Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Prestige Brands Returns to Profit in Fourth Quarter

By Pharmaceutical Processing | May 16, 2013

Prestige Brands Holdings Inc. returned to a profit in its fiscal fourth quarter, benefiting from lower operating expenses and better sales of over-the-counter health care products.

The company, which distributes over-the-counter and household cleaning products like Clear Eyes and PediaCare, reported net income of $19.3 million, or 37 cents per share, for the three months ended March 31. That compares with a loss of $15,000, or breakeven results, a year earlier.

Taking out a deferred tax benefit and other items, earnings were 36 cents per share. Analysts, on average, expected earnings of 34 cents per share, according to a FactSet survey.

Total operating expenses fell to $37.9 million from $45.9 million. Prestige also had a smaller debt extinguishment loss in the current quarter.

Revenue increased 15 percent to $154.5 million from $134 million, with revenue for the over-the-counter health care unit up 22 percent. Wall Street was looking for $157.4 million in revenue.

The health care segment’s performance has been helped by the acquisition of some brands from GlaxoSmithKline PLC.

Last year Prestige paid $660 million to buy 17 over-the-counter product brands from GlaxoSmithKline, including the Beano, Gaviscon and Tagamet gastrointestinal brands, BC and Goody’s pain relievers, and Sominex sleep aids.

Revenue for core over-the-counter brands climbed 9.3 percent in the quarter.

Revenue for the household cleaning division — which makes up less than 15 percent of total revenue — fell 14.5 percent to $20.7 million.

For the year, Prestige earned $65.5 million, or $1.27 per share. In the previous year the Tarrytown, N.Y., company earned $37.2 million, or 73 cents per share. Adjusted earnings were $1.50 per share.

Annual revenue rose 41 percent to $623.6 million from $441.1 million.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE